The control cohort included 48 patients with wild‐type or mutated transthyretin amyloidosis (n = 34), AA amyloidosis (n = 1), or hypertrophic cardiomyopathy unrelated to an amyloidosis process (n = 13). This evidence concerns the gene TTR and AA amyloidosis.